Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

New setback for angiogenesis inhibitors

New setback for angiogenesis inhibitors Inpharma 1369 - 11 Jan 2003 New setback for angiogenesis inhibitors The failure of the angiogenesis inhibitor bevacizumab [avastin] in phase III clinical trials among patients with metastatic breast cancer is a further setback for research in this field, reports Nature Biotechnology. Angiogenesis inhibitors, which prevent the creation of new blood vessels, have previously been heralded as important weapons in the fight against cancer. According to the report, the drugs prevent tumour growth by blocking growth factor activity, by inhibiting the matrix metalloproteinases responsible for breaking down the extracellular matrix and allowing blood vessels to spread, or by directly targeting endothelial cells. They have shown great promise in animal models but their results in clinical trials to date have been disappointing. Semaxanib [SU5416], AGM 1470 [TNP-470] and oglufanide [IM862] have all failed phase III clinical trials, says the report. The latest failure by bevacizumab, which directly targets vascular endothelial growth factor (VEGF), combined with the failure of semaxanib, which targets the VEGF receptor, raise doubts about the suitability of VEGF as a target. According to the report, researchers at the University of Toronto have suggested that current research may be fundamentally flawed, as it is based on the assumption http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Inpharma Weekly Springer Journals

New setback for angiogenesis inhibitors

Inpharma Weekly , Volume 1369 (1) – Feb 9, 2013
Download PDF
1 page

New setback for angiogenesis inhibitors

Abstract

Inpharma 1369 - 11 Jan 2003 New setback for angiogenesis inhibitors The failure of the angiogenesis inhibitor bevacizumab [avastin] in phase III clinical trials among patients with metastatic breast cancer is a further setback for research in this field, reports Nature Biotechnology. Angiogenesis inhibitors, which prevent the creation of new blood vessels, have previously been heralded as important weapons in the fight against cancer. According to the report, the drugs prevent tumour growth...
Loading next page...
 
/lp/springer-journals/new-setback-for-angiogenesis-inhibitors-zEmRCLGls9

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis International Ltd
Subject
Pharmacy; Pharmacy
ISSN
1173-8324
eISSN
2230-6056
DOI
10.2165/00128413-200313690-00003
Publisher site
See Article on Publisher Site

Abstract

Inpharma 1369 - 11 Jan 2003 New setback for angiogenesis inhibitors The failure of the angiogenesis inhibitor bevacizumab [avastin] in phase III clinical trials among patients with metastatic breast cancer is a further setback for research in this field, reports Nature Biotechnology. Angiogenesis inhibitors, which prevent the creation of new blood vessels, have previously been heralded as important weapons in the fight against cancer. According to the report, the drugs prevent tumour growth by blocking growth factor activity, by inhibiting the matrix metalloproteinases responsible for breaking down the extracellular matrix and allowing blood vessels to spread, or by directly targeting endothelial cells. They have shown great promise in animal models but their results in clinical trials to date have been disappointing. Semaxanib [SU5416], AGM 1470 [TNP-470] and oglufanide [IM862] have all failed phase III clinical trials, says the report. The latest failure by bevacizumab, which directly targets vascular endothelial growth factor (VEGF), combined with the failure of semaxanib, which targets the VEGF receptor, raise doubts about the suitability of VEGF as a target. According to the report, researchers at the University of Toronto have suggested that current research may be fundamentally flawed, as it is based on the assumption

Journal

Inpharma Weekly – Springer Journals

Published: Feb 9, 2013

There are no references for this article.